

ESTIMATING SIZE-SPECIFIC NUMBERS OF ACTIVE PHARMACEUTICAL INGREDIENT PARTICLES IN THE REGIONAL DEPOSITION OF A NASAL SPRAY

Julia S. Kimbell, Ph.D.,¹ Jeffry D. Schroeter, Ph.D.,² Geng Tian, Ph.D.,³ Ross Walenga, Ph.D.,³ Andrew Babiskin, Ph.D.,³ and Renishkumar R. Delvadia, Ph.D.³

¹Department of Otolaryngology - Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ²Applied Research Associates, Raleigh, NC, USA; ³U.S. Food and Drug Administration, Silver Spring, MD, USA

INTRODUCTION

- Regional deposition of sprayed corticosteroid droplets are needed to quantify nasal drug delivery
- Computational fluid dynamics (CFD) → simulate sprayed particle transport in three-dimensional (3D) nasal reconstructions
- Most nasal sprays contain active pharmaceutical ingredient (API) particle suspensions in liquid vehicles
- API particle size may affect mucosal dissolution, absorption, and transport rates
- A method is needed to estimate the number and size of API particles in nasal spray deposits to determine API dose and systemic uptake

3D Model Construction

From package Nozzle positioned as instructed

Anatomical regions created

METHODS

- Subject: 26 year old male, 6'0", 69.4 kg, with allergic rhinitis, unknown smoking history, history
 of fluticasone propionate (FP) nasal spray use, otherwise normal
- 3D reconstruction created from CT scan (0.7-mm resolution) using 3D Slicer
- 3D spray nozzle reconstruction positioned in nasal vestibule according to instructions from package insert [1], subtracted from airspace using ICEM-CFD[™] v15.0 (ANSYS, Inc., Canonsburg, PA)
- Anatomical regions of interest created for post-processing using ICEM-CFD[™]
- Hybrid computational mesh of nasal airspace constructed using ICEM-CFD[™] [2]
- Steady-state inspiratory resting airflow simulated using Fluent[™] v14.5 (ANSYS)
- Instructions for use \rightarrow "Breathe gently inwards through the nostril"
- Pressure drop obtained for airflow at twice estimated minute volume [3] with nostrils open
- Right nostril closed, pressure at left nostril and outlet set to 0 and -18.7 Pa, respectively, air velocity set to 0 at airway walls ("no-slip" condition) → airflow rate of 6.4 L/min



Spray Simulation

Droplet size distribution



Volume of spray = 100 μL Size increments = 5 μm

Lognormal distribution:

 $f(x) = \frac{1}{x\sqrt{2\pi}\ln\sigma_g} exp\left[-\frac{(\ln x - \ln x_0)^2}{2(\ln\sigma_g)^2}\right]$ x₀ is the volume median diameter (x50) = 46.6 µm



Spray release location and direction

Droplet transport simulated [4], regional deposited mass computed using Fluent[™]

- Mean adult actuation force of 56.9 N (N, Newtons) [5]
- Droplet size distribution and spray speed measured for 100mg FP spray [6]
- Spray cone angle = 70° [7]

Using solid-cone injections in Fluent's[™] Discrete Phase Model; averaging 5 repeated runs

- Size-specific numbers of API particles computed in regional spray mass
 - Regional API mass assumed proportional to regional spray mass (50 µg FP per spray)
 - Example API particle size distribution from Raman chemical imaging [8]
 - FP density (1.32 g/cm³) \rightarrow "frequency mass fraction" for each size bin



• Frequency mass fractions applied to regional deposited API mass, spherical volume used to estimate numbers of particles per API size bin in each region

Estimation of API Particle Numbers

ChemImage

| Max Chord (μm) | Mid-Chord (µm) | Frequency [Nelson] | Frequency Mass (µg) | Freq. Mass Fraction |
|-------------------|-------------------|-----------------------|---------------------|------------------------|
| 0-0.99 | 0.5 | 1 | 8.639E-08 | 3.125E-05 |
| 1-1.99 | 1.5 | 6 | 1.400E-05 | 5.063E-03 |
| 2-2.99 | 2.5 | 9 | 9.719E-05 | 3.516E-02 |
| 3-3.99 | 3.5 | 2 | 5.927E-05 | 2.144E-02 |
| 4-4.99 | 4.5 | 2 | 1.260E-04 | 4.557E-02 |
| 5-5.99 | 5.5 | 3 | 3.450E-04 | 1.248E-01 |
| 6-6.99 | 6.5 | 1 | 1.898E-04 | 6.866E-02 |
| 7-7.99 | 7.5 | 2 | 5.832E-04 | 2.110E-01 |
| 8-8.99 | 8.5 | 0 | 0.000E+00 | 0.000E+00 |
| 9-9.99 | 9.5 | 0 | 0.000E+00 | 0.000E+00 |
| 10-10.99 | 10.5 | 0 | 0.000E+00 | 0.000E+00 |
| 11-11.99 | 11.5 | 0 | 0.000E+00 | 0.000E+00 |
| 12-12.99 | 12.5 | 1 | 1.350E-03 | 4.883E-01 |





RESULTS

Regional Spray Mass Deposition





CONCLUSIONS



ACKNOWLEDGEMENTS

- A method is presented for estimating size-specific API particle numbers deposited throughout the nasal cavity via spray transport.
- The method estimates that 50 µg of FP in one spray actuation is represented by nearly 500,000 FP particles in nearly 200,000 spray droplets

FUTURE DIRECTIONS

- Obtain additional measurements of particle size distribution (PSD) for FP in nasal sprays
- Estimate FP PSD measurement variation
- Couple deposition predictions with a physiologically-based pharmacokinetic model to predict bioequivalent doses from alternate medication routes

 [1] Medicine, U.S.N.L.o. DailyMed: Label: FLUTICASONE PROPIONATE- fluticasone propionate spray, metered. 2017 [cited 2017 May 23]; Available from:

http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3830675d-b45e-fc97-1f73-674b1fc38c80.

[2] Wofford, M.R., Kimbell, J.S., Frank-Ito, D.O., Dhandha, V., McKinney, K.A., Fleischman, G.M., Ebert, C.S., Jr., Zanation, A.M., and Senior, B.A., A computational study of functional endoscopic sinus surgery and maxillary sinus drug delivery. Rhinology, 2015. 53(1): p. 41-8.

- [3] Garcia, G.J., Schroeter, J.D., Segal, R.A., Stanek, J., Foureman, G.L., and Kimbell, J.S., Dosimetry of nasal uptake of water-soluble and reactive gases: a first study of interhuman variability. Inhal Toxicol, 2009.
 21(7): p. 607-18.
- [4] Kimbell, J.S., Schroeter, J.D., Sheth, P., Tian, G., Delvadia, R.R., Saluja, B., and Walenga, R.L., Effect of Actuation Force on Simulated Regional Nasal Spray Deposition in a Healthy Nasal Cavity, in Respiratory Drug Delivery 2016, R.N. Dalby, et al., Editors. 2016, Virginia Commonwealth University: Richmond, VA. p. 587-590.
- [5] Doughty, D.V., Vibbert, C., Kewalramani, A., Bollinger, M.E., and Dalby, R.N., Automated actuation of nasal spray products: determination and comparison of adult and pediatric settings. Drug Dev Ind Pharm, 2011. 37(3): p. 359-66.
- [6] Schroeter, J.D., Kimbell, J.S., Saluja, B., Delvadia, R.R., Vallorz, E., and Sheth, P., The Impact of Actuation Force on Droplet Size Distribution and Spray Duration of Three Commercially Available Nasal Sprays, in Respiratory Drug Delivery 2016, R.N. Dalby, et al., Editors. 2016, Virginia Commonwealth University: Richmond, VA. p. 261-264.
- [7] Cheng, Y.S., Holmes, T.D., Gao, J., Guilmette, R.A., Li, S., Surakitbanharn, Y., and Rowlings, C.,
- Characterization of nasal spray pumps and deposition pattern in a replica of the human nasal airway. J Aerosol Med, 2001. **14**(2): p. 267-80.

[8] Nelson, M.P., Klueva, O., and Treado, P.J., An Ingredient-Specific Method for Particle Size Characterization of Corticosteroid Nasal Sprays, in Excipient Fest 2008. 2008: San Juan, Puerto Rico. Funding was provided by Grant U01FD005201, from the Department of Health and Human Services (DHHS), Food and Drug Administration. Views expressed in this presentation do not necessarily reflect the official policies of the DHHS; nor does any mention of trade names, commercial practices or organizations imply endorsement by the United States Government.



